06.11.2020 | Original Article | Ausgabe 3/2021
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
Haeseong Park, Kerry Williams, Nikolaos A. Trikalinos, Sarah Larson, Benjamin Tan, Saiama Waqar, Rama Suresh, Daniel Morgensztern, Brian A. Van Tine, Ramaswamy Govindan, Jingqin Luo, A. Craig Lockhart, Andrea Wang-Gillam
09.11.2020 | Original Article | Ausgabe 3/2021
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects
X. Zhu, Y. Ding, Y. Yu, M. Wang, W. Zhou, J. Wang, X. Zhu, H. Zhang, M. Wang, K. Chai, X. Zhang, A. Luk, W. Jiang, S. Liu, Q. Zhang
09.11.2020 | Original Article | Ausgabe 3/2021
Open Access
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
Madusha Meemanage, Lindsay C. Spender, Diane Collinson, Joanna Iannetta, Pranavi Challapalli, Julie Turbitt, Caroline Clark, Mark Baxter, Graeme Murray, Shaun Walsh, Zofia Miedzybrodzka, Russell D. Petty
02.01.2021 | Original Article | Ausgabe 3/2021
Open Access
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
Kumiko Umemoto, Hideaki Takahashi, Chigusa Morizane, Ikuhiro Yamada, Satoshi Shimizu, Kazuhiko Shioji, Yukio Yoshida, Masayo Motoya, Nobumasa Mizuno, Yasushi Kojima, Takeshi Terashima, Kazuhiro Uesugi, Makoto Ueno, Junji Furuse, Tetsuo Akimoto, Masafumi Ikeda
